Park National Corp’s Axsome Therapeutics AXSM Stock Holding History

Park National Corp’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$214K	Buy	+873	New	+$189K	0.01%	302

Other funds holding AXSM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

TAM

Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return

Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Park National Corp's AXSM Position: Q2 2026 in Review

Park National Corp opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 873 shares worth $214K. The stake represents 0.01% of the portfolio and ranks #302 among its holdings.

38 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Park National Corp held 873 shares of Axsome Therapeutics worth $214K as of Q2 2026.
Axsome Therapeutics was a new Park National Corp position in Q2 2026.
Axsome Therapeutics made up 0.01% of Park National Corp's portfolio in Q2 2026, its #302 holding.
38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Park National Corp's 13F filing for Q2 2026, filed 15 Jul 2026.